AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01446484 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil
Description: Immunosuppressant; oral daily dose starting Day 2-3 until withdrawal or end of the study
Study NCT01446484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Immunosuppressant; oral daily dose starting Day 2-3 until withdrawal or end of the study
Study NCT01446484 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus
Description: Immunosuppressant; oral daily dose starting no earlier then after Month 1 post-transplant until withdrawal or end of the study
Study NCT01446484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Immunosuppressant; oral daily dose starting no earlier then after Month 1 post-transplant until withdrawal or end of the study
Study NCT01497483 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pravastatin alone
Description: Pravastatin 40 mg with placebo.
Study NCT01446484 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Immunosuppressant; daily dose starting Day 0 until withdrawal or end of the study
Study NCT01446484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Immunosuppressant; daily dose starting Day 0 until withdrawal or end of the study
Study NCT01446484 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine
Description: Immunosuppressant; daily dose starting Day 0 until withdrawal or end of the study
Study NCT01446484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Immunosuppressant; daily dose starting Day 0 until withdrawal or end of the study
Study NCT01446484 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Description: Immunosuppressant; oral daily dose starting no earlier then after Month 1 post-transplant until withdrawal or end of the study
Study NCT01446484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Immunosuppressant; oral daily dose starting no earlier then after Month 1 post-transplant until withdrawal or end of the study
Study NCT01446484 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Kidney transplantation
Description: Living related kidney transplantation
Study NCT01446484 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Kidney transplantation
Description: Living related kidney transplantation
Study NCT03490201 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Market Approved RF Ablation System
Description: Subjects receive ablation using an FDA approved radiofrequency (RF) ablation system.
Study NCT03490201 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FlexAbility SE Ablation Catheter
Description: Subjects receive ablation treatment using an ablation system that is not FDA approved.
Study NCT05809245 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Corneal neurotization
Description: Autologous sural nerve will be harvested or cadaveric nerve graft will be coapted to an intact sensory branch of the trigeminal nerve. The nerve will be separated into fascicles which will be tunneled under the conjunctiva around the cornea near the limbus.
Study NCT01497483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin and Cyclosporine
Description: Pravastatin 40 mg co-administered with 200 mg of cyclosporine.
Study NCT01548872 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HTK solution
Description: 50 ml/kg bolus in 2 minutes
Study NCT01548872 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: crystalloid cardioplegia solution
Description: 30 ml/kg bolus in two minutes
Study NCT01076803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanreotide (acetate)
Description: Deep subcutaneous injection into the upper external quadrant of the right or the left buttock.
Study NCT01144884 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Procedure (education and exercise)
Description: education/exercise
Study NCT03083483 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation (tDCS)
Description: tDCS will apply a low, direct current for the duration of the study session while the subject is training the specific laparoscopic tasks.
Study NCT03083483 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current stimulation (tDCS)
Description: tDCS will apply a low, direct current for the duration of the study session while the subject is training the specific laparoscopic tasks.
Study NCT02012647 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: Participants sit in a chair that looks like one in a dentist's office. A magnetic coil will be placed on the scalp on one side of the head, overlying the brain's motor cortex to stimulate the brain's output to the muscles in the opposite hand. A second magnetic coil will be placed on the scalp of the opposite side. Recordings from both hands will be made using the magnetic coils placed on scalp. Results will be compared for participants with and without Parkinson's Disease.
Study NCT02012647 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: Participants sit in a chair that looks like one in a dentist's office. A magnetic coil will be placed on the scalp on one side of the head, overlying the brain's motor cortex to stimulate the brain's output to the muscles in the opposite hand. A second magnetic coil will be placed on the scalp of the opposite side. Recordings from both hands will be made using the magnetic coils placed on scalp. Results will be compared for participants with and without Parkinson's Disease.
Study NCT02012647 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Motor Physiology Testing
Description: Participants will be asked to move their upper and lower limbs while seated in a chair. Wireless EMG sensors placed on arm and leg muscles will record measurements during this procedure. Upper and lower limb testing will be performed separately.
Study NCT02012647 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Motor Physiology Testing
Description: Participants will be asked to move their upper and lower limbs while seated in a chair. Wireless EMG sensors placed on arm and leg muscles will record measurements during this procedure. Upper and lower limb testing will be performed separately.
Study NCT06543147 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: breast cancer and breast self- examination education
Description: The experimental group were given education about breast cancer and BSE. Slide presentations used during training provided information about breast anatomy and physiology, breast cancer symptoms and risk factors, early diagnosis methods for breast cancer and breast cancer screening programs, and barriers to breast cancer screening programs were discussed. In addition to slide presentations about breast cancer and BSE, women were also given BSE training on a breast examination mannequin and given brochures after training. The training lasted 40-50 minutes. After women in the experimental group were given training, they were called by telephone once per month until 6 months and reminded about doing BSE.
Study NCT03490201 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FlexAbility SE Ablation Catheter
Description: Subjects receive ablation treatment using an ablation system that is not FDA approved.
Study NCT03683420 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: The intervention consists of using an iPod to listen to music for up to 60 minutes while patients are receiving chemo infusion. There are no on components to the study.
Study NCT03252847 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: AAV5-RPGR
Description: Single, subretinal administration of AAV5-RPGR
Study NCT02733003 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Women's Health CoOp (WHC)
Description: Participants in this group will participate in two workshops of the woman-focused intervention about HIV/STIs, sexual behaviors, alcohol and other drug use, violence, communication skills, and other issues.
Study NCT02028234 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoprazole,
Description: os, 20 mg, once per day, for 30 days
Study NCT02028234 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole
Description: os, 20 mg, once per day, for 30 days
Study NCT03246256 — intervention group
Intervention type: OTHER
Intervention: Group 1
Study NCT02503423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX660
Description: described above
Study NCT01368900 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ulthera® System treatment
Description: Focused ultrasound energy delivered below the surface of the skin.
Study NCT04590534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chromax
Description: Treatment of BPH by Chromax for 3 Months
Study NCT04590534 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildosin Group
Description: patients will receive one capsule of Sidosin 8 mg once daily for 12 weeks
Study NCT04590534 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Group
Description: patients will receive placebo 3 times daily for 12 weeks
Study NCT00005810 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Study NCT00005810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Study NCT00005810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Study NCT00005810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: estramustine phosphate sodium
Study NCT04027348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given IV
Study NCT04027348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Description: Given IV
Study NCT04027348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide
Description: Given IV
Study NCT04104451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corlicyte
Description: expanded umbilical cord lining mesenchymal stem cells
Study NCT03943966 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: 18F-GP1 PET CT
Description: PET CT scan using platelet radiotracer 18F-GP1
Study NCT03943966 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-GP1 PET CT
Description: PET CT scan using platelet radiotracer 18F-GP1
Study NCT04737902 — intervention group
Intervention type: PROCEDURE
Intervention: Erector spinae plane block
Description: Unilateral ESP block was performed between T3 and T7 levels depending on the thoracic surgical incision. The patient is placed in lateral decubitus position, under sterile conditions, a high frequency (6-15 MHz) linear-array transducer (Sonosite® Edge II, Bothell, USA) was placed in a longitudinal parasagittal orientation 2 cm from the posterior midline to visualise the tips of the transverse processes deep to the erector spinae muscle (ESM). A 21 G, 50 mm or 100 mm needle (Pajunk UniPlex NanoLine; Germany) was advanced in-plane with the ultrasound beam. The needle tip was directed to the plane between the transverse process and the posterior fascia of the ESM. Correct needle tip location was confirmed by ultrasound visualisation of linear fluid spread in the fascial plane. The injection of 0.5 to 1 ml of bupivacaine was 0.5% with epinephrine 5 µg/ml; then, a total of 20-30 ml of the same local anaesthetic was administered.
Study NCT04247659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium aescinate
Description: The main mechanism of sodium aescinate includes anti - inflammatory, anti - exudate anti - oxygen free radical ,anti - edema increased venous tension.The treatment course of sodium aescinate is 10 days,20mg/day, intravenous infusion.
Study NCT02475603 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total knee arthroplasty
Description: Total knee arthroplasty
Study NCT02277743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Subcutaneous injection alternated among the different quadrants of the abdomen, upper thighs and upper arms
Study NCT02277743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (for Dupilumab)
Description: Subcutaneous injection alternated among the different quadrants of the abdomen, upper thighs and upper arms
Study NCT01224158 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental Power Toothbrush
Description: Following a placebo mouthwash phase, Subjects will be asked to brush their teeth (twice per day with the experimental toothbrush and toothpaste provided) moving to the next quadrant of the mouth at 30-second intervals.
Study NCT01224158 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Flat trimmed Manual Toothbrush
Description: Following a placebo mouthwash phase, Subjects will be asked to brush their teeth (twice per day using the toothbrush and toothpaste provided) in their usual manner.
Study NCT02055157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMN 111
Description: BMN 111 will be administered daily for 24 months in an open-label sequential dose adjustment fashion.
Study NCT00733499 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: LCS Complete Duofix
Description: Orthopaedic implant for total knee replacement with Duofix biological fixation surfaces
Study NCT00733499 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LCS Complete Porocoat
Description: Orthopaedic implant for total knee replacement with Porocoat biological fixation surfaces
Study NCT01382329 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H5N1 (pre-)pandemic influenza vaccine (whole virion, Vero Cell derived, inactivated)
Description: Intramuscular injection into the musculus deltoideus or subcutaneous injection in the upper arm
Study NCT04508608 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Stress Gated blood pool SPECT
Description: After labeling of red blood cells in vivo, a sequential series of acquisition is carried out at rest and during increasing doses of dobutamine (5/10/15 μg / kg / min). The duration of acquisition is 300 seconds.~The acquisitions are carried out on dedicated cardiac gamma-camera with ultrafast Cadmium zinc telluride (CZT) detectors (DiscoveryNM530c, General electric Healthcare Israel, Israel)
Study NCT04508608 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Dynamic SPECT
Description: The passage of a radiopharmaceutical bolus through the cavities of the heart and myocardium at rest and during infusion of adenosine at a dosage of 140 mcg / kg / min (for 4 minutes) is recorded.~At the peak of the stress test (after 2 minutes of administration of adenosine), a 5 ml bolus (dose 260-444 MBq) of 99mTc-methoxyisobutylisonitrile (MIBI) is administered at a rate of 1 ml / s. Immediately after the end of tracer administration, 30 ml of 0.9% sodium chloride (NaCl) is infused. A scintigraphic recording of the study begins 5 seconds before the administration of the radiopharmaceutical.~The next day, the study at rest is carried out. Scintigraphic images are recorded in tomographic mode with ECG synchronization for 600 s, at list mode.~The acquisitions are carried out on dedicated cardiac gamma-camera with ultrafast CZT detectors (DiscoveryNM530c, General electric Healthcare Israel, Israel)
Study NCT01299519 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight Maintenance
Description: Subjects in the weight maintenance arm will maintain a steady body weight (plus or minus 2% of initial body weight) for six months.
Study NCT01299519 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Loss
Description: Half of the subjects in the weight loss arm will lose 5% of their weight through a low-calorie diet, and half will also lose 10% and 15% body weight.
Study NCT03988166 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Chronic Total Occlusion Revascularization
Description: Teleflex's series of study guidewires and catheters will be used to facilitate the safe and effective crossing of de novo CTOs and placement of conventional guidewires beyond the lesion via either a true lumen or subintimal pathway.
Study NCT03988166 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: GuideLiner® V3 catheter, TrapLiner® catheter, Turnpike® catheter
Description: GuideLiner® V3 catheter, TrapLiner® catheter, Turnpike® catheter
Study NCT03655925 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: plasmatic HLA-G
Description: plasmatic HLA-G by blood sample
Study NCT03790761 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PREP 8.0 Curriculum
Description: The PREP 8.0 curriculum is an experiential curriculum designed to be implemented in a workshop or educational setting. Using techniques of cognitive-behavioral marital therapy and communication-oriented marital enhancement, PREP aims to help couples achieve high levels of relationship functioning and prevent marital problems. The PREP approach is based on research in the field of relational and marital health and success conducted at the University of Denver.
Study NCT02144922 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pitavastatin
Description: statin
Study NCT02144922 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Life style modification alone
Study NCT03347916 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Strawberry juice as (placebo)
Description: Patients received strawberry juice 5 ml volume, one hour before induction.
Study NCT03347916 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin Oral Solution [Neurontin]
Description: Patients received gabapentin (Neurontin oral solution 250 mg/ml, Pfizer, USA) 5 mg/kg mixed with strawberry juice to constitute 5 ml volume, one hour before induction.
Study NCT00947661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPARC0912
Description: Eye drops, once daily, 12 weeks
Study NCT00947661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference0912
Description: Eye drops, once daily, 12 weeks
Study NCT01886001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povidone-Iodine
Description: Umbilical stump care. Povidone-Iodine, USP, Swabstick Singles, applied once a day to cord stump while umbilical line(s) are in place
Study NCT01886001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Description: Umbilical stump care. Chlorhexidine Gluconate 2% w/v; 70% Isopropyl Alcohol v/v Swabstick Single, applied once a day to cord stump while umbilical line(s) are in place
Study NCT01886001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pluronic
Description: Umbilical stump care. Pluronic gel - (F68, Polymyxin, Nystatin, Nitrofurantoin)applied once a day to cord stump while umbilical line(s) are in place
Study NCT01886001 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: No product is applied to cord stump while umbilical line(s) are in place. This is the current standard of care at UVA.
Study NCT03806283 — intervention group
Intervention type: PROCEDURE
Intervention: Omental Biopsy
Description: The surgeon and clinical care team will conduct the c-section to deliver the baby and the placenta as clinically indicated. After delivery, during the closing procedures, the surgeon will indicate a time for a participating Ob/Gyn physician on the study team to collect the omental bio-specimen. Omentum is frequently excised or removed for clinical reasons during surgical procedures. Omentum has small blood vessels within it that have been used for evaluation of vascular functional changes in research. The investigators wish to isolate one to three vessels of 5 to 7 cm length. The surgeon will then close and the clinical care team will resume their standard of care activities.
Study NCT00966004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM178
Description: oral
Study NCT00966004 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study NCT00966004 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tolterodine
Description: oral
Study NCT00774384 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: NZ MenB OMV vaccine (NZ98/254)
Description: 3 doses by intramuscular injection
Study NCT03078816 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Activa PC Primary Cell Neurostimulator - (Model 37601)
Description: Deep Brain Stimulator system will be implanted using standard neurosurgical techniques. The device will deliver constant stimulation to the thalamus using settings programmed by study team.
Study NCT03078816 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Activa RC Rechargeable Neurostimulator - (Model 37612)
Description: Deep Brain Stimulator system will be implanted using standard neurosurgical techniques. The device will deliver constant stimulation to the thalamus using settings programmed by study team.
Study NCT03078816 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Activa SC Single Cell Neurostimulator (Models 37602/37603)
Description: Deep Brain Stimulator system will be implanted using standard neurosurgical techniques. The device will deliver constant stimulation to the thalamus using settings programmed by study team.
Study NCT03078816 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DBS Lead - (Model 3387
Description: Deep Brain Stimulator system will be implanted using standard neurosurgical techniques. The device will deliver constant stimulation to the thalamus using settings programmed by study team.